77P Experience Pooling Control Arms Within a Complex Phase I Drug-Radiotherapy (RT) Platform Trial

Jamie B. Oughton, J. Kendall, R.H. Phillip,Mark A. Norris, Ashley Horne, O.A. Ojo,Alastair Greystoke,Corinne Faivre‐Finn, F. Walker, P.H. Shaw,K. Franks,Stephen Harrow,Crispin T. Hiley,Anthony J. Chalmers, Stanley B. Brown

ESMO open（2024）

引用 0|浏览0

暂无评分

摘要

CONCORDE is a phase I platform study in NSC lung cancer testing different DNA damage response inhibitor (DDRi) RT combinations to identify the recommended phase II dose of DDRis. It is challenging to estimate toxicity rates and attribute toxicities to DDRi and/or RT, due to the lack of toxicity data on contemporary RT. We outline how we overcame the challenge of toxicity estimation and attribution.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要